Testing an Innovative Biomarker: Expression of HIF-1α and Its Isoforms in the Blood and Skin Tissue of Major Burns
NCT02870439 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2016-08-17
Summary
Burn injury with full-thickness skin damage that encompass large body surface areas can induce local and systemic perturbations that are costly in terms of human suffering as well as in strains on the health care system. Characterization of new major molecular biomarkers involved in this process creates significant diagnostic and therapeutic challenges.
Hypoxia-inducible factor-1 α (HIF-1 α) is a ubiquitously expressed heterodimeric transcription factor comprising an α and a β subunit. It was shown that under normoxic conditions, the HIF-1α subunit is ubiquitinated and degraded, whereas under hypoxic conditions, HIF-1α accumulates, dimerizes with HIF-1β, and activates the transcription of a spectrum of target genes encoding multiple angiogenic growth factors and cytokines of potential importance in wound healing. Seven isoforms of HIF-1α issued from alternative splicing have been identified.
The importance of HIF-1α in wound healing in animal models has been suggested by several studies. Indeed, diminished HIF-1 levels and activity have been documented in conditions of impaired wound healing. The literature review shows a marked reduction of HIF-1α levels in mice in case of burn wound skin that in the case of excisional cutaneous wound. Other studies have shown that the expression of HIF-1α was correlated with the extent and depth of the burns.
This study aims to improve the knowledge on the pathophysiological factors involved in the field of wound healing. The assumptions are based on results of studies done on mice, and this work aims to document these findings in humans.
Objective
The main objective of the study is to compare the variations of expression of HIF-1α measured in blood and skin tissue samples in three groups:
* Subjects with major burn wounds involving more than 20% of the total body surface area;
* Subjects with burn wounds smaller than 5% of total body surface area;
* Subjects with a skin wound after a surgical procedure requiring a skin resection.
Secondary objectives are to compare the expression levels of HIF-1α locally at the burn site to those observed in blood, to evaluate the expression of growth factors produced by HIF-1α target genes (VEGF and EPO) or playing a central role in the healing process (TGF-β1), and to assess the correlation between the expression of HIF-1α and the kinetics of wound healing of the subject rated by evaluation of time of donor sites complete epithelialization.
Material and Methods
We propose to create three groups:
* 15 patients with extensive third degree burns involving more than 20% of the total body surface area;
* 15 patients with less extensive third degree burns, involving less than 5% of body surface area;
* 15 patients with post-surgical wounds with skin resection. Skin and tissue specimens will be collected three times: day 0, 7 and 14 from burned patients (with more than 20% of the total body surface area and less than 5% of body surface area). Samples of skin tissue will be collected within the skin resection from patients with post-surgical wounds at day 0, blood samples will be collected at day 0 and 14.
Conditions
- Burn Injuries
Interventions
- OTHER
-
Blood drawn
Sponsors & Collaborators
-
Assistance Publique Hopitaux De Marseille
lead OTHER
Principal Investigators
-
Urielle DESALBRES · Assistance Publique Hôpitaux de Marseille
-
Aurélie HAUTIER, MD · Assistance Publique Hôpitaux de Marseille
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2016-10-31
- Completion
- 2017-10-31
Countries
- France
Study Locations
More Related Trials
-
Timing of Surgery And Outcome in Burn Patients ( EARLYBURN )
NCT02940171 ·Status: TERMINATED
-
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
NCT05549232 ·Status: COMPLETED
-
Hypoxia-inducible Factor-1 (HIF-1) Regulated Circulating Angiogenic Cells (CACs) Recruitment in Burn Wound Healing
NCT00796627 ·Status: TERMINATED ·Phase: NA
-
Pain and Itch Reduction in Burn Scars Treated With Fractional CO2 Laser
NCT04364217 ·Status: WITHDRAWN ·Phase: NA
-
Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Thermal Burns
NCT07259668 ·Status: RECRUITING
-
Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging
NCT06921421 ·Status: NOT_YET_RECRUITING
-
Non Ablative Fractional Laser Treatment of Burn Scars
NCT02014298 ·Status: COMPLETED ·Phase: NA
-
Utilizing 3D Imaging for Burn Wound Assessment
NCT06938061 ·Status: RECRUITING
-
Study of Silicone Material Inserts To Treat Burn Scars
NCT03159182 ·Status: WITHDRAWN ·Phase: NA
-
Understanding Coagulation and Inflammation in Burns
NCT03077269 ·Status: TERMINATED
-
Allogenic Stem Cell Therapy in Patients With Acute Burn
NCT01443689 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate
NCT00732485 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A Feasibility Study of a Novel Phototherapy System for the Management of Acute Burns
NCT04011306 ·Status: UNKNOWN ·Phase: NA
-
Potential Benefits of Laser Treatment on Skin Blood Flow and Sweating in Burn Survivors
NCT04947449 ·Status: TERMINATED
-
Chronology of Occult and Gross Coagulopathy in Burn Patients
NCT01638481 ·Status: COMPLETED
-
Examine the Validity of a Panel of Objective Burn Scar Measurement Tools
NCT05126017 ·Status: UNKNOWN
-
Burn Injuries During COVID-19 Pandemic and Its Influence on Length of Stay
NCT06330389 ·Status: COMPLETED
-
The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars
NCT01488240 ·Status: RECRUITING ·Phase: NA
-
CO2 Laser Revision for Burn Related Donor Site Scars
NCT04456127 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Wound Healing and Pain Management in Partial Thickness Burns
NCT01289340 ·Status: WITHDRAWN
-
Remote Ischemic Conditioning to Reduce Burn Wound Progression
NCT03027596 ·Status: UNKNOWN ·Phase: NA
-
HLA Sensitization in Severely Burned Patients
NCT02537821 ·Status: UNKNOWN
-
Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns
NCT02997592 ·Status: COMPLETED ·Phase: NA
-
Large Burn Outcome Study
NCT00731887 ·Status: WITHDRAWN
-
A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)
NCT06440239 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2